The IMvigor010 trial showed that Signatera-guided treatment with Tecentriq improved disease-free survival and overall ...

Seborrheic dermatitis is linked to other epithelial barrier diseases, supporting the epithelial barrier theory as a shared ...

NDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based on positive data from the ...

Mischief-makers can guess the subjects being discussed with LLMs using a side-channel attack, according to Microsoft ...

Introduction Adolescence is a key period of development for mental health; however, little is known about how (cumulative) daily life experiences impact long-term mental health development in this ...

Q3 2025 Earnings Call November 7, 2025 11:00 AM ESTCompany ParticipantsAl Petrie - Officer of Investor RelationsPaul McKinney - ...

Operator: Good afternoon, and welcome to the Beyond Air financial results call for the fiscal quarter ended September 30, 2025.

November 12, 2025 / Tecogen Inc. (NYSE American:TGEN), a leading manufacturer of clean energy products, reported revenues of $7.18 million and net loss of $2.13 million for the quarter ended September ...

-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...

Q2 2026 Earnings Call November 10, 2025 4:30 PM ESTCompany ParticipantsSteven Lisi - CEO & Chairman of the BoardDouglas Larson ...

Namagwa, S. (2025) Governance, Risk, and Regulation: A Framework for Improving Efficiency in Kenyan Pension Funds. Journal of ...

NORTH BILLERICA, MA / ACCESS Newswire / November 12, 2025 / Tecogen Inc. (NYSE American:TGEN), a leading manufacturer of clean energy products, reported revenues of $7.18 million and net loss of $2.13 ...